Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B), while iShares 10 20 Year Treasury Bond ETF trades at $96.55. The key difference: Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| RXRX | TLH | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $105.36 |
52-Week Low | $2.84 | $96.39 |
Enterprise Value | $1.33B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
